

Item 8.01

Other Events.

On February 14, 2018, Cellular Biomedicine Group, Inc., through its wholly-owned subsidiary, Cellular Biomedicine Group HK Ltd. (collectively, the “Company”), entered into an agreement with the Augusta University Research Institute, Inc. (the “University”), which agreement grants the Company the exclusive option (the “Option”) to negotiate in good faith a royalty-bearing, exclusive license to certain patent rights owned by the University relating to an invention to identify novel alpha fetoprotein specific T-cell receptors for a hepatocellular carcinoma immunotherapy (the “Technology”). The term of the Option is 36 months, during which time the Company may elect to commence negotiations for an exclusive license or sublicense to the Technology with the University. Once the Company exercises the Option, the parties will have six months from the exercise date to negotiate and finalize a definitive license agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,
Inc.

Date: February 15, 2018 By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Executive Officer